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Purpose:To introduce the concept of dose–mass-based inverse optimization for radiother-
apy applications.
Materials and Methods: Mathematical derivation of the dose–mass-based formalism is
presented. This mathematical representation is compared to the most commonly used
dose–volume-based formulation used in inverse optimization. A simple example on digitally
created phantom is presented.The phantom consists of three regions: a target surrounded
by high- and low-density regions. The target is irradiated with two beams through those
regions and inverse optimization with dose–volume and dose–mass-based objective func-
tions is performed. The basic properties of the two optimization types are demonstrated
on the phantom.
Results: It is demonstrated that dose–volume optimization is a special case of dose–mass
optimization. In a homogenous media, dose–mass optimization turns into dose–volume
optimization.The dose calculations performed on the digital phantom show that in this very
simple case dose–mass optimization tends to penalize more the dose delivery through the
high-density region and therefore it results in delivering more dose through the low-density
region.
Conclusion: It was demonstrated that dose–mass-based optimization is mathematically
more general than dose–volume-based optimization. In the case of constant density media,
dose–mass optimization transforms into dose–volume optimization.
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INTRODUCTION
Modern radiotherapy treatment planning relies on the dose–
volume-histogram (DVH) paradigm, where doses to volumes of
anatomical structures are employed (1–4). The widespread use of
DVHs is rooted within the wealth of clinical information as well as
clinician’s experience with dose–volume metrics (5). DVHs were
introduced more than three decades ago, while intensity modu-
lated radiotherapy (IMRT) was developed a decade later (4, 6–10).
At those times, homogeneous dose calculations were the norm,
with heterogeneous dose calculations hardly even possible, and
therefore, not practical for a routine use. In recent years, how-
ever, it has been argued that the effects of delivered dose seem to
be more closely related to healthy tissue toxicity (and thereby to
clinical outcomes) when dose to mass, or dose–mass-histograms
(DMHs), are considered in treatment plan review and evaluation
(11–16).
Dose–mass-histograms were introduced for evaluation and
review of thoracic treatment plans (15, 16). Shortly, after their
introduction, a rationale for their application was outlined (11,
12). In those publications, it was argued that DVHs of the lungs are
breathing phase dependent, while DMHs are not (11). Investiga-
tion on the difference between DVHs and DMHs and their effects
on the treatment outcomes showed that the range of deviation
between them is very large (12). It was concluded that “the effec-
tiveness of the dose distribution delivered to the patients seems to be
more closely related to the radiation effects when using theDMH con-
cept” (12). Similar conclusions that “DMH may be more relevant
than DVH” were drawn in an investigation of DVH and DMH
effects on 4D lung treatment plans (14).
MATHEMATICAL FRAMEWORK OF DMH INVERSE IMRT
OPTIMIZATION
Consider DVH-based IMRT optimization, where plans are
designed through a number of dose–volume objectives (4, 17, 18).
The optimization algorithm divides each beam’s cross-sectional
plane into a 2D-array of finite size beamlets, which initially are
assigned equal weights. With the initiation of the optimization
those weights are varied (optimized), such that 2D intensity maps
of variable intensities are created, with the aim of maximizing
dose to targets, while at the same time minimizing doses to adja-
cent organs at risk (OARs). The doses to all volumes of interest
(VOIs), resulting from those intensity maps from all beams, give
rise to a set of optimization functions Fj, j = 1, . . . , n, where j
runs over all the objectives specified for all VOIs, including targets
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and OARs. Those optimization functions are a mathematical
representation of
F =
∑N
j=1 F
j (1)
IMRT objectives. The inverse optimization algorithm aims in
minimizing a composite objective function given by Eq. 1. This
function is a sum of all individual optimization objectives.
F j =
∑
i∈V
(
di − d j
d j
)2
∆vi (2)
For each VOI there might be, none or more than one Fj speci-
fied, depending on the aims of the radiotherapy plan. Equation
2 describes an example of a quadratic objective function (18). V
denotes the volume of the VOI for which Fj is evaluated, di is
the dose in voxel (3D volume element) i, dj is the desired dose
in each voxel, and vi is the normalized (with respect to the entire
VOI volume) voxel volume. The summation can be over the entire
(min/max dose objectives) or partial (DVH-objectives) volume V
of the VOI. The quadratic term in Eq. 2 makes the functions Fj
always positive, thereby requiring the optimization to find only
a minimum, i.e., to minimize the differences between individual
voxel doses and the desired dose for the specified objective. The
normalization with respect to the desired dose dj and to total organ
volume in the equation terms, respectively, scales all functions Fj
such that the contributions from targets and OARs in the global
optimization of F are of the same magnitude and a global com-
posite objective function (cf. Eq. 1) can be constructed. Note that,
if the voxels of the dose grid (cf. Eq. 2) are of equal volumes the
corresponding∆vi for most of the voxels will be the same, and can
be moved in front of the summation. This makes the sum of Eq. 2
only partially dependent on volumes∆vi. This partial dependence
is because of partial volume effects, where given VOI occupies only
a fraction of a given dose voxel i, and ∆vi for that dose voxel is
different from ∆vi for the dose voxels, which are fully contained
in the VOI.
The implementation of tissue mass information and convert-
ing volume-based optimization into mass-based optimization can
be achieved through Eq. 3, where the last term represents the voxel
mass, normalized to the total VOI mass.
F j =
∑
i∈V
(
di − d j
d j
)2
∆mi (3)
If the mass term in Eq. 3 is expanded then the mass-based
objective function will be represented by Eq. 4, where ρi is the
averaged density in voxel i. Usually, the dose voxels in
F j =
∑
i∈V
(
di − d j
d j
)2
∆mi =
∑
i∈V
(
di − d j
d j
)2
× ρi × vi∑
k∈V ρk × vk
(4)
radiotherapy treatment planning are much larger than the voxels
of the of the underlying computed tomography (CT) data. There-
fore, the density in the dose voxel is an averaged from the CT
density derived from the raw CT data through a CT-to-density
calibration tables.
It follows from Eq. 4 that in the situation where the density
in all dose voxels is constant (i.e., CT scan of a uniform den-
sity object), there should be no difference between DVH-based
and DMH-based optimizations, since Eq. 4 would be transformed
into Eq. 2. Constant density ρ= ρi = ρk can be moved in front of
the summation in Eq. 4 and it will cancel out. Therefore, mass-
based optimization for heterogeneous media will naturally remove
a degree of degeneracy, inherent to volume-based optimization. It
must be stressed out that from mathematical and physical stand
points DMH-based optimization is a more general approach than
DVH-based optimization in radiotherapy applications. If the den-
sity across a VOI is variable, ∆mi in Eq. 4 will change from
voxel-to-voxel in addition to partial volume effects mentioned
above. This difference in the functional forms of the optimization
functions Fj will result in IMRT solutions for DMH optimiza-
tion, which may differ from the solutions achieved through DVH
optimization.
EXAMPLE
A simple example will be presented to illustrate the basic points of
the derived framework for mass-based optimization and to outline
the differences with dose–volume-based optimization. Consider
the experimental set-up presented on Figure 1. The figure depicts
a digital phantom in an axial view. The phantom consists of three
10 cm× 10 cm× 10 cm cubes with densities of 0.2 (yellow), 0.8
(red), and 1.0 (green) g/cm3, respectively. In the middle of the
green VOI, there is a cylindrical target with diameter and length
of 3 cm. The target was irradiated with an anterior–posterior (AP)
and a lateral (Lat) beam centered on the geometric center (isocen-
ter) of the target. In the first experiment, target was irradiated
with the AP and the Lat beams through 2 cm× 2 cm open aper-
tures with the goal to deliver 500 cGy to 95% of the volume. The
weights of the two beams were set equal. 833 monitor units (MUs)
were required for that target dose prescription to be achieved. 474
MUs were delivered through the high-density (red) region, while,
not surprisingly, only 359 MUs were delivered through the low
density (yellow). In other words, 57% of the dose came through
the high-density region and 43% was delivered through the low-
density region, since the absorption in the high-density region is
larger.
The same phantom is used in a different example where the
high (red) and low (yellow) density regions are combined to form
an “organ at risk” (OAR) to which the dose should be minimized
through an inverse optimization. The two beams – AP and Lat –
were allowed to have only one IMRT segment each. Two plans
were generated – one where the cost function for OAR dose opti-
mization was constructed according to Eq. 2, and another one
where the OAR dose optimization was based on Eq. 3. Those opti-
mizations were termed DVH and DMH, respectively. With each
optimization the dose to the OAR was iteratively decreased until
the standard deviation of the dose across the target reached 6% of
the prescription dose, i.e., no more than 30 cGy. The dose–volume
histograms (DVHs) of the two optimization approaches are pre-
sented on Figure 2. It is evident form the figure that while the
high-tail dose to the low-density region (yellow) is higher with
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FIGURE 1 |The experimental set-up used to demonstrate the dose–mass
concept. It is realized through a digitally constructed phantom, consisting of
three cubical volumes (VOIs) with dimensions 10 cm×10 cm×10 cm. As
depicted on the figure, the three regions have different densities. In the
middle of the VOI with density of unity, there is a cylindrical target with height
and diameter of 3 cm.
FIGURE 2 | Dose–volume histograms, resulting from DVH and DMH
optimization applied to the phantom presented on Figure 1. The high-
and low-density VOIs have been combined in a single VOI with the aim that
500 cGy are delivered to the target, while the dose to that VOI is minimized
as much as possible.
DMH optimization, the overall DVH for the higher density region
is lower than in the case of DVH optimization. In the DVH opti-
mization, 26.86% of the MUs were delivered through the higher
density region, while the rest 73.14% were delivered through the
lower density region. For the DMH optimization those percent-
ages were 20.62 and 79.38, respectively. Therefore, optimization
based on masses of the VOIs will penalize more the beams con-
tributing dose through the high-density region (AP beam) rather
than through the low density (Lat beam), given that the objec-
tive for the optimization is to minimize the dose delivered to both
high- and low-density VOIs simultaneously. Effectively, for cer-
tain target coverage, more radiation would be delivered through
the low-density region and less through the high-density VOI.
CONCLUSION
A new framework for dose–mass optimization paradigm in inverse
radiotherapy treatment planning was presented. It was shown
through a mathematical derivation that dose–volume-based opti-
mization is a special case of its more general representation realized
through dose–mass optimization. In other words, dose–mass opti-
mization transforms in dose–volume optimization in the case
of constant density media. Simple computational example was
presented to explain the basic properties of the two optimization
types.
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